307 related articles for article (PubMed ID: 15871637)
1. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.
Ragueneau-Majlessi I; Levy RH; Brodie M; Smith D; Shah J; Grundy JS
Clin Pharmacokinet; 2005; 44(5):517-23. PubMed ID: 15871637
[TBL] [Abstract][Full Text] [Related]
2. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.
Levy RH; Ragueneau-Majlessi I; Garnett WR; Schmerler M; Rosenfeld W; Shah J; Pan WJ
J Clin Pharmacol; 2004 Nov; 44(11):1230-4. PubMed ID: 15496640
[TBL] [Abstract][Full Text] [Related]
3. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.
Levy RH; Ragueneau-Majlessi I; Brodie MJ; Smith DF; Shah J; Pan WJ
Ther Drug Monit; 2005 Apr; 27(2):193-8. PubMed ID: 15795651
[TBL] [Abstract][Full Text] [Related]
4. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Griffith SG; Dai Y
Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
[TBL] [Abstract][Full Text] [Related]
5. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers.
Cawello W; Bonn R
J Clin Pharmacol; 2012 Nov; 52(11):1739-48. PubMed ID: 22162508
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
7. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy.
Rosenfeld WE; Liao S; Kramer LD; Anderson G; Palmer M; Levy RH; Nayak RK
Epilepsia; 1997 Mar; 38(3):324-33. PubMed ID: 9070595
[TBL] [Abstract][Full Text] [Related]
9. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
Miljković B; Pokrajac M; Varagić V; Lević Z
Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
[TBL] [Abstract][Full Text] [Related]
10. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
Dutta S; Reed RC
Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration.
Stockis A; Sargentini-Maier ML; Brodie MJ
Epilepsy Res; 2016 Dec; 128():163-168. PubMed ID: 27842261
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and drug interactions with zonisamide.
Sills G; Brodie M
Epilepsia; 2007 Mar; 48(3):435-41. PubMed ID: 17319920
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M
CNS Drugs; 2020 Jun; 34(6):661-672. PubMed ID: 32350749
[TBL] [Abstract][Full Text] [Related]
14. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
Coupez R; Nicolas JM; Browne TR
Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
[TBL] [Abstract][Full Text] [Related]
16. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Sun L; Yagoda S; Yao B; Graham C; von Moltke L
Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
[TBL] [Abstract][Full Text] [Related]
17. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.
Gustavson LE; Sommerville KW; Boellner SW; Witt GF; Guenther HJ; Granneman GR
Am J Ther; 1998 Mar; 5(2):73-9. PubMed ID: 10099041
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.
Ragueneau-Majlessi I; Levy RH; Bergen D; Garnett W; Rosenfeld W; Mather G; Shah J; Grundy JS
Epilepsy Res; 2004 Nov; 62(1):1-11. PubMed ID: 15519127
[TBL] [Abstract][Full Text] [Related]
19. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.
Peters DH; Sorkin EM
Drugs; 1993 May; 45(5):760-87. PubMed ID: 7686468
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction of zonisamide in rats. Effect of zonisamide on other antiepileptics.
Kimura M; Tanaka N; Kimura Y; Miyake K; Kitaura T; Fukuchi H
Biol Pharm Bull; 1993 Jul; 16(7):722-5. PubMed ID: 8401412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
